Biomarkers of Renal Dysfunction in Neuroblastoma Survivors

Completed

• Conditions: Neuroblastoma Survivors

• Registration Number: NCT03947346
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The main purpose of this study is to learn more about biomarkers of kidney function in the blood and urine of neuroblastoma survivors. A biomarker is a biological molecule found in blood, urine, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-05-09
• Study First Submitted: 2019-05-09
• Study First Submitted QC: 2019-05-09
• Study First Posted: 2019-05-13
• Status Verified: 2025-07
• Primary Completion: 2025-07-15
• Study Completion: 2025-07-15
• Last Update Submitted: 2025-07-16
• Last Update Posted: 2025-07-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• Diagnosis of neuroblastoma between 0-18 years of age
• < 21 years of age at time of study enrollment
• Two or more years from completion of systemic chemotherapy and/or radiation therapy

Exclusion Criteria

• Patients treated with observation only
• Patients with multiple primary cancers

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
indicators of renal injury	2 years	urine collected from the first morning void will be used to assess urine creatinine

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States